CON

Concentra Group Holdings Parent, Inc. - 10-Q Summary (Q2 2025)

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2025. Concentra Group Holdings Parent, Inc. (Concentra) is the largest provider of occupational health services in the United States by number of locations. As of June 30, 2025, the Company operated 628 stand-alone occupational health centers in 41 states and 406 onsite health clinics at employer worksites in 43 states. The Company became a fully independent public entity following a distribution from Select Medical Corporation on November 25, 2024.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 15.2% in Q2 2025 and 11.2% YTD 2025 compared to the prior year. This growth was driven by a 9.5% increase in patient visits (Q2) and a 4.4% increase in revenue per visit, alongside the impact of recent acquisitions.
• Acquisitions: The Company completed two significant acquisitions in 2025:
  • Nova Medical Centers: Acquired March 1, 2025, for $265.0 million, adding 67 occupational health centers.
  • Pivot Onsite Innovations: Acquired June 1, 2025, for $54.4 million, adding over 240 onsite health clinics.
• Profitability: While revenue grew, GAAP Net Income decreased due to higher interest expenses from new debt financing and one-time costs related to the separation from Select Medical Corporation and acquisition integration. Adjusted EBITDA increased 13.2% in Q2 and 10.1% YTD.
• Interest Expense: Interest expense rose significantly to $28.2 million in Q2 2025 (from $0.2 million income in Q2 2024) due to the issuance of an $850 million term loan and $650 million senior notes in July 2024, plus incremental borrowings in 2025.
• Debt Structure: In March 2025, the Company amended its Credit Agreement to increase the Revolving Credit Facility to $450 million and added a $102.1 million incremental term loan. The leverage ratio stood at 3.8x as of June 30, 2025.

Guidance, Outlook, Risks, and Unusual Items

• Outlook: Management intends to continue growing through strategic acquisitions and de novo center development. The Company declared a quarterly cash dividend of $0.0625 per share, payable August 28, 2025.
• Unusual Items:
  • Separation Costs: $1.4 million (Q2) and $1.7 million (YTD) in non-recurring separation transaction costs.
  • Acquisition Costs: $2.8 million (Q2) and $6.0 million (YTD) in costs related to the Nova and Pivot acquisitions.
  • Stock Compensation: Increased to $2.3 million (Q2) and $4.6 million (YTD) as the Company operates as a standalone public entity.
• Risks and Contingencies:
  • Litigation: The Company is subject to various legal actions, including a California Department of Insurance investigation regarding billing and coding for physical therapy claims. A consolidated class action lawsuit regarding a 2023 data breach at a third-party vendor (Perry Johnson & Associates) is pending.
  • Regulatory: Ongoing DOJ investigation into physical therapy billing practices (originally targeting Select Medical) continues, with a related qui tam lawsuit recently dismissed but subject to amendment.
  • Interest Rate Risk: The Company has $647.6 million of variable-rate debt exposure not covered by hedges. A 0.25% increase in rates would impact annual interest expense by approximately $1.6 million.

Key Facts for Investor Verification

• Acquisition Integration: Verify the realization of synergies and revenue accretion from the Nova ($265M) and Pivot ($54.4M) acquisitions, which significantly altered the facility count and cost structure.
• Debt Servicing Capacity: Monitor the impact of the increased debt load ($1.67B total) on future cash flows, particularly given the rise in interest expense and the 3.8x leverage ratio.
• Regulatory Exposure: Track the status of the California insurance investigation and the DOJ physical therapy billing investigation, as outcomes could result in significant fines or recoupments.
• Operating Metrics: Confirm the sustainability of the 9.5% increase in patient visits and 4.4% increase in revenue per visit, which drove the top-line growth.
• Dividend Sustainability: Assess whether operating cash flows ($100.1M YTD) are sufficient to support the declared dividend policy alongside capital expenditures and debt service.